Nicotinamide N-methyltransferase (Nnmt) methylates nicotinamide, a form of vitamin B3, to produce N 1 -methylnicotinamide (MNAM). Nnmt has emerged as a metabolic regulator in adipocytes, but its role in the liver, the tissue with the strongest Nnmt expression, is not known. In spite of its overall high expression, here we find that hepatic expression of Nnmt is highly variable and correlates with multiple metabolic parameters in mice and humans. Further, we find that suppression of hepatic Nnmt expression in vivo alters glucose and cholesterol metabolism and that the metabolic effects of Nnmt in the liver are mediated by its product MNAM. Supplementation of high-fat diet with MNAM decreases serum and liver cholesterol and liver triglycerides levels in mice. Mechanistically, increasing Nnmt expression or MNAM levels stabilizes sirtuin 1 protein, an effect that is required for their metabolic benefits. In summary, we describe here a novel regulatory pathway for vitamin B3 that could provide a new opportunity for metabolic disease therapy. npg
Nicotinamide adenine dinucleotide (NAD + ) acts as a redox cofactor for more than 200 enzymatic reactions and serves as a cosubstrate for the sirtuins, a family of NAD + -dependent deacetylases [1] [2] [3] . Sirtuin 1 (Sirt1), the most studied member of the family, has emerged as an important regulator of nutrient metabolism. Sirt1 regulates gluconeogenesis through deacetylation of the peroxisome proliferatoractivated receptor-γ coactivator 1α, forkhead box O 1 (FoxO1) and CREB-regulated transcription coactivator 2, among other factors [4] [5] [6] [7] [8] [9] . Sirt1 also suppresses lipogenesis and cholesterol synthesis partly through direct deacetylation and inhibition of the master regulators of lipid homeostasis, sterol regulatory element binding proteins 1 and 2 (refs. [10] [11] [12] . Absence of Sirt1 from the liver accelerates the metabolic disturbances of a high-fat diet (HFD) [13] [14] [15] . Conversely, increased Sirt1 activity generally confers a metabolically beneficial profile. Transgenic overexpression of Sirt1 or increased availability of the Sirt1 substrate, NAD + , ameliorates many of the metabolic consequences of diet-induced obesity (DIO) in rodents, such as glucose intolerance, cholesterol and fat deposition in the liver, endoplasmic reticulum stress and inflammation, although adverse effects were also reported [16] [17] [18] [19] [20] [21] . The activity of Sirt1 itself is regulated through multiple mechanisms including interaction with other proteins and post-translational modifications, both areas of current research [22] [23] [24] . In addition, Sirt1 is regulated by the availability of its substrate, NAD + , and may act as a sensor for metabolic adaptation to nutritional states. Thus enzymes in NAD + metabolic pathways may regulate metabolism through Sirt1 (refs. 25,26) . Nnmt is one such enzyme, shown recently to regulate adipose tissue energy expenditure partly through global changes in histone methylation and increased NAD + content 27 . Nnmt methylates nicotinamide (NAM) to N 1 -methylnicotinamide (MNAM) using the universal methyl donor S-adenosyl methionine (SAM), and produces S-adenosyl homocysteine (SAH) [28] [29] [30] . MNAM is further oxidized by aldehyde oxidase in the liver to two related compounds, 1-methyl-2-pyridone-5-carboxamide and 1-methyl-4-pyridone-3carboxamide, and all three are excreted in the urine 31 . Liver is the tissue with the strongest Nnmt expression, but its role in this tissue is not well understood. Here we examine the role of Nnmt in the liver and demonstrate that Nnmt regulates glucose, lipid and cholesterol metabolism by stabilizing Sirt1.
RESULTS

Nnmt expression correlates with metabolic parameters
It has been recently shown that expression of Nnmt in adipose tissue is increased in mouse models of obesity 27 . For this reason, we examined the regulation of Nnmt expression in the liver by diet and in metabolic disease models. Nnmt expression was higher in the livers of db/db mice compared with controls, as previously shown 27 (Supplementary Fig. 1a ). Nnmt expression was lower in the livers of mice fed a ketogenic diet and higher in the livers of calorically restricted mice compared with chow-fed mice. HFD feeding did not change liver Nnmt expression ( Supplementary  Fig. 1b) . Similarly, MNAM content in the liver was not changed by feeding with HFD compared with chow (chow 2.88 ± 0.44 versus a r t i c l e s 8 8 8 VOLUME 21 | NUMBER 8 | AUGUST 2015 nature medicine HFD 3.19 ± 0.35 pmol/mg wet weight, n = 8 per group, data are mean ± s.e.m.). Fasting and re-feeding experiments had no effect on liver Nnmt expression in C57BL6/J mice (Supplementary Fig. 1c ). Liver Nnmt expression varies widely (~100-fold) among mouse inbred strains (Supplementary Fig. 2 ). We took advantage of this property and correlated liver Nnmt expression with metabolic phenotypes deposited in the Hybrid Mouse Diversity Panel database, which aims to find novel genetic variations that influence metabolic diseases 32 . Liver Nnmt expression correlates inversely with high-density lipoprotein (HDL), total cholesterol, triglycerides (TGs), free fatty acids and other parameters ( Supplementary Table 1 ). This correlation prompted us to examine the role of Nnmt in metabolic homeostasis.
Nnmt regulates glucose and cholesterol metabolism
To establish a causal role for Nnmt in regulating some of these metabolic parameters, we manipulated Nnmt expression through adenoviral knockdown and overexpression in mouse primary hepatocytes and in vivo. We initially tested the role of Nnmt in gluconeogenesis, as this was the first reported metabolic pathway regulated by Sirt1 (ref. 4). Primary hepatocytes with Nnmt knockdown (Fig. 1a ) had significantly lower hepatocyte glucose output (50%) and significantly lower expression of genes encoding both glucose-6-phosphatase catalytic (G6pc) (20%) and phosphoenolpyruvate carboxykinase 1 cytosolic (Pck1) (40%) compared with control hepatocytes (Fig. 1b) . In contrast, primary hepatocytes in which Nnmt was overexpressed ( Fig. 1c ) had significantly higher glucose output (1.4-fold), threefold higher expression of G6pc and fourfold higher expression of Pck1 compared with control hepatocytes (Fig. 1d) . These data indicate that Nnmt is a positive regulator of gluconeogenesis in primary hepatocytes.
To test the role of Nnmt in vivo, we knocked down Nnmt in the liver of C57BL6/J mice using adenovirus. Nnmt-knockdown mice had significantly lower overnight fasting glucose levels compared with control mice, whereas fasting insulin did not change ( Fig. 1e) . Pyruvate conversion to glucose was significantly lower in mice with Nnmt knockdown (50%), suggesting reduced gluconeogenesis in vivo (Fig. 1f) . Expression of G6pc and fructose bisphosphatase 1 (Fbp1) was lower in the livers from Nnmt-knockdown mice compared with control mice, whereas Pck1 and pyruvate carboxylase (Pcx) expression was unchanged ( Fig. 1g) . Serum and hepatic TG levels did not differ (data not shown), but serum and liver cholesterol levels were significantly higher in ad libitum-fed Nnmt-knockdown mice compared with controls ( Fig. 1h ). Expression of Srebf2; the first two genes in the cholesterol synthesis pathway (Hmgcr and Hmgcs1); and Abcg5, Scarb1, and Abcb11 (encoding several receptors and transporters in the cholesterol pathway) were also higher (1.3-to 2-fold) in the livers of Nnmt-knockdown mice compared with controls ( Fig. 1i) .
Our results show that Nnmt is a novel regulator of hepatic glucose and cholesterol metabolism in vivo.
To explore the potential role of NNMT in human physiology, we examined the correlation between liver NNMT expression and multiple metabolic parameters in a cohort of obese non-diabetic individuals (Supplementary Table 2 ). Liver NNMT correlated positively with glucose infusion rate (P = 0.03), suggesting enhanced glucose disposal ( Table 1) . We found significant inverse correlations between shcontrol shNnmt
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Relative mRNA expression Nnmt Actin Nnmt AdNnmt AdNnmt liver NNMT expression, total cholesterol (P < 0.0001) and low-density lipoprotein (LDL) cholesterol levels (P < 0.0001), fasting TG levels (P < 0.03) and cortisol levels (P < 0.045) ( Table 1 ). The most robust correlations were observed between NNMT and cholesterol (total and LDL) ( Fig. 2a,b ). The coefficients of determination, R 2 = 0.348 for total cholesterol and R 2 = 0.41 for LDL cholesterol, suggest that variation in human liver NNMT expression can account for as much as 35-40% of the variation in the serum cholesterol of our subjects. In addition, liver inflammation decreased with increasing NNMT expression ( Fig. 2c) . These results implicate liver NNMT in human physiology.
Sirt1 is required for the metabolic actions of Nnmt
To explore whether Sirt1 is involved in the metabolic effects of Nnmt, we assessed the acetylation status of FoxO1, a well-regarded target of Sirt1, and used it as an indicator of Sirt1 activity. Acetylation of FoxO1 was significantly higher in primary hepatocytes with Nnmt knockdown in vitro compared with controls, indicating decreased Sirt1 activity (Fig. 3a) . The opposite was also true, as we found that FoxO1 acetylation was significantly lower in primary hepatocytes overexpressing Nnmt in vitro compared with controls ( Fig. 3b) . The livers of mice with Nnmt knockdown had significantly higher FoxO1 acetylation compared with control mice (more than fourfold), suggesting impaired Sirt1 activity in vivo ( Fig. 3c) .
To test the causal involvement of Sirt1 in mediating the effects of Nnmt, we treated primary hepatocytes with the Sirt1 inhibitors sirtinol and EX-527. G6pc and Pck1 expression was significantly lower in inhibitortreated hepatocytes compared with untreated hepatocytes overexpressing Nnmt (Fig. 3d,e ). Pretreatment with the specific Sirt1 inhibitor EX-527 significantly lowered glucose production in inhibitor-treated hepatocytes compared with untreated hepatocytes overexpressing Nnmt (Fig. 3f) . We also speculated that increasing Sirt1 expression should rescue the effects of Nnmt knockdown on the expression of gluconeogenic genes. As expected, adenoviral overexpression of Sirt1 rescued the suppression of G6pc and Pck1 expression caused by Nnmt knockdown, showing that Sirt1 is both necessary and sufficient to mediate the effects of Nnmt on gluconeogenesis ( Fig. 3g) .
Nnmt regulates Sirt1 stability
To investigate how Nnmt affects Sirt1 activity and metabolic pathways, we measured the content of Nnmt substrates and products, SAM, SAH, NAM and MNAM, and the Sirt1 substrate, NAD + . The SAM/SAH ratio, intracellular NAD + and NAM content were not different in primary hepatocytes with Nnmt knockdown in vitro and in the livers of mice with Nnmt knockdown in vivo compared with controls ( Supplementary Fig. 3a-c) . Only the product of Nnmt, MNAM, showed changes that were consistent with changes in Nnmt expression. Intracellular MNAM content was significantly higher (~2.5-fold) in primary hepatocytes overexpressing Nnmt in vitro compared with controls ( Supplementary Fig. 3d ). MNAM content was below the detection limit in primary hepatocytes with Nnmt knockdown in vitro and was lower (30%) in the livers of mice with Nnmt knockdown in vivo compared with controls ( Supplementary Fig. 3d ).
As neither the SAM/SAH ratio nor NAD + content, previously shown to be higher in adipocytes from Nnmt-knockdown mice 27 , were changed in hepatocytes, we considered alternative ways in which Nnmt might be regulating Sirt1-dependent pathways. In particular, we examined whether Nnmt affects Sirt1 itself and noticed that expression of Sirt1 protein was significantly higher (more than tenfold) in primary hepatocytes overexpressing Nnmt in vitro ( Fig. 4a ) and significantly lower (50%) in primary hepatocytes with Nnmt knockdown in vitro compared with controls ( Fig. 4b) . As an additional control, expression of Nampt, the enzyme regulating the limiting step in the nicotinamide salvage pathway, was not affected by changes in Nnmt expression ( Fig. 4a,b) . Sirt1 protein was also significantly lower in the livers of Nnmt knockdown mice compared with control mice (Fig. 4c ).
In the same experiments, Sirt1 mRNA expression was not changed, suggesting that Nnmt might be regulating the stability of Sirt1 protein. We measured Sirt1 half-life in primary hepatocytes treated with cyclohexamide, an inhibitor of protein translation. Sirt1 half-life was longer in hepatocytes overexpressing Nnmt (>25 h) compared with control (AdGFP) hepatocytes (10 h) ( Fig. 4d) . In human liver biopsies, SIRT1 protein correlated positively with NNMT expression (r = 0.797, n = 12) ( Fig. 4e) .
Regulation of Sirt1 protein stability is not well understood. Previous studies implicate the proteasome in the degradation of Sirt1 through ubiquitin-dependent and independent pathways and through caspase-mediated degradation [33] [34] [35] . We treated primary hepatocytes with the proteasome inhibitor MG132 for up to 20 h because toxicity ensues at a later time. Thus expression of Sirt1 protein was Pearson's correlation coefficient (r) and P values for associations between expression of NNMT in liver and selected metabolic parameters in the subjects (n = 51). The significant associations persisted after excluding subjects taking hypolipidemic drugs (n = 10). npg modestly higher (~2-fold) compared with untreated hepatocytes and was comparable to that seen with Nnmt overexpression over the same time course (Supplementary Fig. 4a ). In addition, the difference in Sirt1 protein expression between control and NNMT-overexpressing hepatocytes was much smaller in MG132-treated cells, consistent with the idea that Nnmt inhibits proteasome degradation of Sirt1. We treated cells with MG132 to accumulate ubiquitinated proteins and showed that Nnmt overexpression lowers Sirt1 ubiquitination ( Supplementary Fig. 4b ), but does not affect general proteasome activity ( Supplementary Fig. 4c ).
MNAM mediates the metabolic function of Nnmt
Because Nnmt is an enzyme, we examined whether its enzymatic activity is required for the increased Sirt1 protein expression. To generate enzymatically inactive Nnmt, we modeled NAM into the available X-ray structure of mouse Nnmt and selected to independently mutate tyrosine 20 (Y20) and alanine 198 (A198) to tryptophan ( Supplementary  Fig. 5a ) [36] [37] [38] , predicting that increasing the bulkiness of the side chain would disrupt NAM binding and thus Nnmt activity. We expressed wildtype Nnmt (Nnmt-wt) and the mutants Nnmt-Y20W and Nnmt-A198W in a heterologous cell line and tested the immunoprecipitated proteins for their ability to methylate NAM. In contrast to wild-type Nnmt, neither Nnmt mutant was able to methylate NAM in the presence of its co-substrate SAM, despite similar amounts of Nnmt protein in the extracts (Supplementary Fig. 5b,c) . Next, we co-transfected Sirt1 with either wild-type or mutated Nnmt to test their ability to increase Sirt1 protein expression, and confirmed that Nnmt activity is required for this effect (Supplementary Fig. 5d ).
These observations led us to test MNAM, the product of Nnmt. Although traditionally considered an inactive or toxic metabolite of terminal nicotinamide clearance, some publications suggest that, at pharmacological doses, MNAM has biological activity and affects endothelial cell function [39] [40] [41] . Addition of MNAM to the primary hepatocyte medium resulted in threefold-higher intracellular MNAM content compared with controls ( Fig. 4f ). Similar to Nnmt overexpression, MNAM-treated hepatocytes showed a dose-dependent increase in Sirt1 protein expression compared with controls ( Fig. 4g) and in G6pc and Pck1 mRNA expression without affecting Sirt1 or Nnmt mRNA expression ( Fig. 4h) . Consistent with the higher G6pc and Pck1 expression, MNAM-treated hepatocytes had higher glucose production (twofold) compared with controls, and these changes were abolished by Sirt1 knockdown (Fig. 4i,j) . MNAM-treated cells had lower ubiquitinated Sirt1 protein without affecting general proteasome activity ( Supplementary Fig. 5e,f) , and MNAM does not directly affect Sirt1 activity in vitro (Supplementary Fig. 5g ).
MNAM improves the metabolic profile of HFD-fed mice
Increasing Sirt1 expression improves the metabolic profile of DIO mice 16, 17, 42 . Because the small metabolite MNAM mediates the metabolic activity of Nnmt, we expected that in vivo treatment with MNAM would increase liver Sirt1 protein and improve the metabolic profile of mice fed an HFD. To test this idea, we fed several cohorts of wild-type C57BL6/J mice an HFD supplemented with different doses of MNAM (0.3% and 1%) for several weeks. MNAM content was fourfold higher in the livers of MNAM-supplemented (HFD1%) compared with control mice (HFD), indicating that it is orally bioavailable (Supplementary Fig. 6a ). HFD-fed mice gained an additional 7 g of body weight after 8 weeks compared with mice fed low-fat control diet (CD), but MNAM supplementation had no effect on body weight gain ( Supplementary Fig. 6b ). Expression of Sirt1 protein in liver was significantly lower (50%) in HFD-fed compared with CD-fed mice (Fig. 5a) . MNAM-supplemented mice had higher liver Sirt1 protein expression compared with mice fed HFD alone and beyond the levels seen on CD (Fig. 5a) . The mRNA expression of Sirt1 followed the opposite pattern from the protein, suggesting that HFD regulates Sirt1 protein stability and MNAM reverses this effect (Fig. 5a) .
Consistent with higher Sirt1 protein expression, liver FoxO1 acetylation was significantly lower in the livers of MNAM-supplemented mice (HFD1%) compared with control mice (HFD) (Fig. 5b) . MNAM prevented the changes in fasting glucose and insulin caused by HFD, but this effect was transient and persisted only for 1 week (Fig. 5c) . More sustained effects were seen on lipids and cholesterol. npg Serum TGs were not affected by HFD or MNAM treatment throughout the course of the studies (data not shown), but MNAM-treated mice (HFD1%) had significantly lower liver TGs (60%) compared with control mice (HFD) (Fig. 5d) , and the pattern of gene expression suggested that fatty acid synthesis is inhibited by MNAM (Supplementary Fig. 6c ). Indeed, ex vivo hepatocytes isolated from mice treated with MNAM (HFD1%) had significantly lower fatty acid synthesis (58%) compared with control hepatocytes (HFD) (Fig. 5d) . HFD-fed mice had significantly higher serum cholesterol compared with control mice (CD) and MNAM supplementation of HFD prevented this increase for several weeks (Fig. 5e) , although by 8 weeks the effect was no longer apparent (data not shown).
We also analyzed the lipoprotein profile to determine the size of the particles carrying cholesterol. Plasma from HFD-fed mice had higher cholesterol content in HDL fractions (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) and in intermediate fractions (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) compared with CD-fed mice (Fig. 5f) . MNAMtreated mice (HFD1%) had lower cholesterol in the intermediate fractions (20-30) compared with HFD-fed mice, suggesting a selective effect on the more atherogenic lipoprotein particles (Fig. 5f) . After 8 weeks on HFD, liver cholesterol was significantly lower (75%) in MNAM-treated mice (HFD versus HFD1%) ( Fig. 5g) . Fecal cholesterol output was also lower in MNAM-treated mice compared with HFD alone, suggesting that the lower liver cholesterol was due to the decreased synthesis and not increased cholesterol clearance (Fig. 5g) . As expected, cholesterol synthesis was lower (75%) in hepatocytes isolated from MNAM-treated mice (HFD1%) compared with control hepatocytes (HFD) (Fig. 5g) .
A gene expression survey of cholesterol metabolic pathways was consistent with the liver cholesterol profile. Expression of the master cholesterol regulators Srebf2 and Nr1h3 (encoding LXRα) and several of their target genes in cholesterol synthesis (Srebf2, Hmgcs1) and transport (Ldlr, Abca1, Abcg8) was significantly higher in the livers of HFD-fed compared with CD-fed mice, and MNAM supplementation of HFD prevented these changes in a dose-dependent manner (Supplementary Fig. 6d,e) . Consistent with the improved metabolic profile of the liver, MNAM-fed mice had significantly lower liver expression of the proinflammatory cytokines Tnf and Il6 compared with HFD-fed mice (Supplementary Fig. 6f) . To test if the metabolic effects of MNAM require Sirt1 activity in vivo, we fed mice HFD supplemented with MNAM in combination with the Sirt1 inhibitor EX-527. Sirt1 inhibition blocked the beneficial effects of MNAM on liver cholesterol and liver TGs. Changes in serum cholesterol showed similar trends but did not reach significance (Fig. 5h) . Our data indicate that pharmacological doses of MNAM improve the metabolic dysregulation caused by HFD feeding. A schematic representation of the proposed pathway shows NAM increasing Sirt1 activity through NAD + biosynthesis and Sirt1 protein through Nnmt and MNAM (Fig. 5i) .
DISCUSSION
Nnmt has recently emerged as a novel metabolic regulator 27 . Expression of Nnmt in adipose tissue correlates positively with adiposity in mice, and antisense oligonucleotide knockdown of Nnmt protected against DIO 27 .
In humans, expression of NNMT in adipose tissue and its product MNAM correlates positively with insulin resistance 43 . The function of Nnmt in the liver, a site of major Nnmt expression, is not well investigated. Dietary regulation of liver Nnmt expression shows some interesting patterns. Ketogenic diet feeding significantly suppresses liver Nnmt expression, which may contribute to the increased serum and liver cholesterol in this dietary model 44 .
Of considerable interest is the increased Nnmt expression in C57BL6 mice under caloric restriction, as this would promote Sirt1 protein stability, which mediates many of the metabolic effects of caloric restriction 16 . Other strains of mice show a much more impressive response. Caloric restriction of the outbred ICR (Institute for Cancer Research) mice increases liver Nnmt expression 36.5-fold 45 . The contribution of Nnmt to the metabolic benefits of caloric restriction should be addressed in future experiments. Our data do not support the idea that downregulation of Nnmt expression contributes to the pathogenesis of obesity, at least in the models tested, as Nnmt expression was either unchanged or even increased in the livers of HFD-fed and db/db mice, respectively. Liver Nnmt is a major variable expression locus in mice 46 , and it correlates inversely with serum cholesterol, TGs and free fatty acid levels among other markers. We observed similar associations in a human obese cohort with significant inverse correlation between liver NNMT expression and serum total cholesterol, LDL cholesterol, TG levels and other parameters. The most significant associations are between NNMT and LDL cholesterol, accounting for up to 40% of the variation in LDL cholesterol in our cohort, which could potentially explain a large fraction of the variation in cholesterol in other human populations as well. Altogether, associations from mice and npg humans suggest that increased liver NNMT expression correlates with an improved metabolic profile, in contrast to its expression in adipose tissue 27, 43 . We speculate that the significant variation in liver NNMT expression underlies the natural variation in metabolic traits seen among mice and humans, and that individuals with lower expression of NNMT in liver could be predisposed to the deleterious consequences of nutrient excess.
We tested the causal role of Nnmt in metabolic regulation by adenoviral knockdown and overexpression in vitro and in vivo in mice, and showed that Nnmt regulates hepatic glucose, lipid and cholesterol metabolism. The mechanism of action underlying this regulation by Nnmt in the liver is completely different from that in adipose tissue. Nnmt is not a major methyltransferase in the liver and does not change methyl donor balance in hepatocytes, in contrast to adipocytes and cancer cells 27, 47 . This is not surprising, as liver expresses other major methyltransferases that account for the majority of the methyl donor flux in this tissue 48 . Instead, we found that the metabolic effects of Nnmt are mediated by its product MNAM. Both Nnmt and MNAM increase Sirt1 protein expression independent of its mRNA levels, whereas Sirt1 is necessary for the metabolic effects of Nnmt and MNAM. Our results are consistent with a large body of literature implicating Sirt1 in the regulation of gluconeogenesis and cholesterol synthesis 4, 6, 7, 11 .
The stability of Sirt1 itself is poorly understood, and alternative pathways have been proposed 34, 35, 49 . Our data suggest that Nnmt and MNAM regulate the ubiquitin-proteasome degradation of Sirt1. Whether MNAM binds directly to Sirt1 itself or another protein involved in Sirt1 degradation is not known. Very recently, Mdm2 has been proposed as the Sirt1 E3-ligase and represents a potential candidate 50 . MNAM has long been considered an inactive metabolite. Recent studies show that it possesses anti-inflammatory and antithrombotic activity with an incompletely understood mechanism of action, and also increases Caenorhabditis elegans life span through mitohormetic effects 39, 40, 51 . Our results define a novel intracellular mechanism for the metabolic effects of Nnmt through the production of the active endogenous metabolite MNAM that could be applicable to other cell types where Nnmt is strongly expressed, such as adipose tissue, endothelium, cancer cells and possibly on cells not expressing Nnmt through paracrine effects of secreted MNAM.
We anticipated beneficial effects of dietary MNAM supplementation in mice fed an HFD because MNAM increased Sirt1 protein expression in vivo [16] [17] [18] . In line with the known metabolic effects of Sirt1, MNAM significantly lowered liver cholesterol and TG levels, while also suppressing fatty acid and cholesterol synthesis and the expression of lipogenic and cholesterol synthesis genes. MNAM supplementation also suppressed the expression of several target genes of Nr1h3 (encoding Lxrα) and Nr1h4 (encoding Fxr) in cholesterol and bile acid transport. It has been previously shown that Sirt1 deacetylates and activates Lxrα and Fxr 52, 53 , therefore the reduction in their target genes is likely indirect and secondary to the reduced availability of their ligands due to the suppression of cholesterol synthesis.
We also observed systemic effects of MNAM with significant lowering of serum cholesterol and changes in lipoprotein profile. Mouse lipoprotein metabolism differs from that of humans, as most of the cholesterol is transported in HDL and not LDL. MNAM supplementation produced a selective decrease in larger lipoprotein particles and not HDL, suggesting that MNAM or its derivatives could be used to decrease LDL levels in humans. Serum TG levels did not change in our experiments. However, it should be noted that HFD and C57BL6 mice are not ideal models of triglyceridemia and that a TG-lowering effect of MNAM has been reported in a rat model in the context of a high-fructose diet 41 .
Methylation of NAM by Nnmt is a major pathway for the clearance of excess vitamin B3 from the body. Here we ascribe it a novel and unexpected function in Sirt1-dependent metabolic regulation. Thus in addition to well-established NAD + biosynthetic pathways, which stimulate Sirt1 activity by increasing NAD + levels, vitamin B3 clearance pathways also regulate hepatic nutrient metabolism through MNAM-mediated Sirt1 protein stabilization.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
analyser II (Beckman Instruments, Brea, California). Duplicate samples were used for serum insulin determination by the immunoradiometric assay (Medgenix Diagnostics, Fleunes, Belgium). The coefficients of variation (intra-assay) were 5.2% at a concentration of 10 mU/liter and 3.4% at 130 mU/liter. The coefficients of variation (inter-assay) were 6.9% and 4.5% at 14 and 89 mU/liter, respectively. Total serum cholesterol was measured by an enzymatic, colorimetric method through the cholesterol esterase/cholesterol oxidase/peroxidase reaction (Cobas CHOL2). HDL cholesterol was quantified by a homogeneous enzymatic colorimetric assay through the cholesterol esterase/cholesterol oxidase/peroxidase reaction (Cobas HDLC3). Total serum TGs were measured by an enzymatic, colorimetric method with glycerol phosphate oxidase and peroxidase (Cobas TRIGL). LDL cholesterol was calculated using the Friedewald formula. Cortisol was determined by routine laboratory test.
Euglycemic hyperinsulinemic clamp (human). Insulin action was determined by the euglycemic hyperinsulinemic clamp. After an overnight fast, two catheters were inserted into an antecubital vein, one for each arm, used to administer constant infusions of glucose and insulin, and to obtain arterialized venous blood samples. A 2-h euglycemic hyperinsulinemic clamp was initiated by a two-step primed infusion of insulin (80 mU/m 2 /min for 5 min, 60 mU/m 2 /min for 5 min) immediately followed by a continuous infusion of insulin at a rate of 40 mU/m 2 /min (regular insulin; Actrapid, Novo Nordisk, NJ). Glucose infusion began at minute 4 at an initial perfusion rate of 2 mg/kg/min, then was adjusted to maintain plasma glucose concentration at 4.9-5.5 mmol/liter. Blood samples were collected every 5 min for determination of plasma glucose and insulin. Insulin sensitivity was assessed as the mean glucose infusion rate during the last 40 min. In the stationary equilibrium, the amount of glucose administered (M) equals the glucose taken by the body tissues and is a measure of overall insulin sensitivity.
Gene expression analyses (human).
RNA was prepared from liver biopsies using the RNeasy Lipid Tissue Mini Kit (QIAgen; Gaithersburg, MD). The integrity of each RNA sample was evaluated by the Agilent Bioanalyzer (Agilent Technologies; Palo Alto, CA). Total RNA was quantified spectrophotometrically (GeneQuant, GE Health Care; Piscataway, NJ) or with the bioanalyzer. Three µg of RNA were reverse transcribed to cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems; Darmstadt, Germany) according to the manufacturer's protocol.
Gene expression was measured by real-time quantitative PCR using the LightCycler 480 Real-Time PCR System (Roche Diagnostics; Barcelona, Spain), using TaqMan technology suitable for relative gene expression quantification. The reaction was performed in a final volume of 12 µl following the manufacturer's protocol. The cycle program consisted of an initial denaturation for 10 min at 95 °C followed by 40 cycles of 15 s denaturing phase at 92 °C, 1 min annealing and extension phase at 60 °C. The prevalidated TaqMan primer/probe set for cyclophilin was used as the endogenous control for the target genes in each reaction: cyclophilin A (PPIA; Hs99999904_m1, RefSeq. NM_021130.3). Prevalidated SybrGreen primers for human Nnmt were purchased from Roche Diagnostics (Barcelona, Spain). Primer sequences are as follows: NNMT forward: 5′-AGCTGGAGAAGTGGCTGAAG-3′ and NNMT reverse: 5′-TGGACCCTTGACTCTGTTCC-3′.
The Second Derivative Maximum Method was used for the determination of the crossing points (Cp). A Cp value was obtained for each amplification curve and ∆Cp value was first calculated by subtracting the Cp value for human PPIA cDNA from the Cp value for each sample and transcript. Fold changes compared with the endogenous control were then determined by calculating 2 −∆Cp , so gene expression results are expressed in all cases as expression ratio relative to PPIA gene expression, according to manufacturer's guidelines.
FoxO1 acetylation. Hepatocytes (8 × 10 5 ) were plated into six-well plates and infected with a control or Nnmt overexpressing adenovirus overnight. Next day the cells were infected again with the virus expressing FoxO1. After 24 h, the cells were harvested in 200 µl of high-salt lysis buffer (1% Triton, 500 mM NaCl, 50 mM Tris-HCl, pH 7.4, and inhibitors). After 30 min incubation on ice, lysates were centrifuged at full speed for 30 min at 4 °C. The supernatant was diluted with 2 volumes of dilution buffer (50 mM Tris-HCl, pH 7.4, with inhibitors) to bring down the concentration of Triton and salt. Total protein (250 µg) from each sample was incubated with 2 µg of FoxO1 primary antibody overnight at 4 °C. The next day 40 µl of protein A/G slurry was added for another 4 h. The beads were then washed 3 times with wash buffer (0.3% Triton, 150 mM NaCl, 50 mM Tris-HCl) After the final wash, the beads were eluted with 40 µl 2× sample buffer and boiled at 95 degree for 5 min. The eluate (20 µl) was resolved by SDS-PAGE gel and probed with the indicated antibodies. For liver endogenous FoxO1 acetylation assay, liver pieces were lysed and immunoprecipitated as described above. Briefly, 4 mg of total proteins were incubated with 2 µg of primary antibody overnight and then 40 µl of protein A/G slurry for 4 h. The beads were then washed with wash buffer and eluted with 50 µl 2× sample buffer; 20 µl of the eluate was loaded for western blot analysis.
HPLC methods. Hepatocytes infected with adenoviruses as described and treated with 1 mM of nicotinamide for 24 h. Medium was collected, centrifuged for 5 min and injected into HPLC for NAM and MNAM analysis. Hepatocytes were harvested in ice-cold 80% methanol and incubated at −80 °C for 15 min. After centrifugation, the supernatant was dried under vacuum, resuspended in dH 2 O and analyzed by HPLC. 6-Methylnicotinamide was included as an internal standard to account for sample loss during extraction. The metabolites were separated on Atlantis T3 column (4.6 mm id, 100 mm length) using the Breeze System (Waters, MA) protected by a 20 mm guard column. Metabolites were eluted isocratically in 20 mM KH 2 PO 4 pH 3, 5% methanol, 2 mM sodium heptanesulfonic acid at a 0.7 ml/min flow rate. NAM and MNAM were detected by UV absorption at 260 nm and identified by retention time compared with standards.
Sirt1 degradation. Primary hepatocytes were infected with a control or Nnmtoverexpressing adenovirus overnight and cultured for additional 24 h. The cells were then treated with cyclohexamide 10 µg/ml and harvested at different time points in RIPA buffer with inhibitors. Total protein (10 µg) from each sample was resolved by SDS-PAGE gel and probed with the indicated antibodies.
HEK293T transfection. HEK293T were originally purchased from ATCC and maintained in DMEM-HG containing 10% FBS. Cells were transfected with 0.05 µg plasmid encoding HA-Sirt1 along with 0.5 µg of plasmid encoding either GFP, Flag-Nnmt-wt, Flag-Nnmt-Y20W or Flag-Nnmt-A198W with Lipofectamine 2000 (Invitrogen). At 48 h after the transfection, cells were rinsed with PBS and harvested in RIPA buffer. Total protein (10 µg) from each sample was resolved by SDS-PAGE gel and probed with the indicated antibodies.
Proteasome assay. HEK293T cells were lysed on ice for 30 min in the lysis buffer provided in the 20S Proteasome assay kit (Cayman Chemicals, Ann Arbor, MI) and spun for 30 min. The supernatant was transferred to a new tube and incubated with increasing concentrations of MNAM for 15 min at room temperature. The proteasome activity of the supernatant was measured following manufacturer's instructions. The proteasome inhibitor MG132 was used as a positive control.
MNAM treatment. Primary hepatocytes were plated as described. After a 5 h attachment period, hepatocytes were treated with different concentrations of MNAM. After 24 h, fresh medium was added (containing NAM) and the incubation continued for another 18 h before harvesting in RIPA buffer. Total protein (10 µg) from each sample was resolved by SDS-PAGE gel and probed with the indicated antibodies.
Sirt1 activity assay. Direct effect of MNAM on Sirt1 activity was measured by the Sirt1 Direct Fluorescent Screening Assay Kit (Cayman Chemicals, An Arbor, MI) following manufacturer's recommendations.
HFD experiments. The 7-to 8-week-old wild-type C57BL6/J male mice were purchased from The Jackson Laboratory. After 1-week acclimatization, mice were fed HFD supplemented with MNAM. Individual mice were randomly allocated to each experimental group. The only criterion was a matched group mean weight. Mice were group-housed with food and water available ad libitum. Irradiated HFD (RD12451) and control diet (RD12450K) were
